Brokerages forecast that Immunomedics (NASDAQ:IMMU) will report ($0.13) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Immunomedics’ earnings, with estimates ranging from ($0.21) to ($0.04). Immunomedics posted earnings per share of ($0.22) in the same quarter last year, which would suggest a positive year over year growth rate of 40.9%. The business is expected to report its next earnings report on Wednesday, May 9th.
According to Zacks, analysts expect that Immunomedics will report full-year earnings of ($0.96) per share for the current year, with EPS estimates ranging from ($1.07) to ($0.85). For the next year, analysts expect that the company will report earnings of ($0.23) per share, with EPS estimates ranging from ($0.96) to $0.50. Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for Immunomedics.
Immunomedics (NASDAQ:IMMU) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.09). The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $0.90 million.
IMMU has been the subject of a number of research reports. ValuEngine cut shares of Immunomedics from a “hold” rating to a “sell” rating in a research note on Friday, January 5th. Jefferies Group raised their target price on shares of Immunomedics from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. BidaskClub raised shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 25th. TheStreet raised shares of Immunomedics from a “d” rating to a “c-” rating in a research note on Friday, February 9th. Finally, Zacks Investment Research downgraded shares of Immunomedics from a “hold” rating to a “sell” rating in a research note on Saturday, February 17th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $19.00.
Shares of NASDAQ IMMU traded down $0.20 during mid-day trading on Tuesday, reaching $16.50. 1,143,272 shares of the company were exchanged, compared to its average volume of 1,736,771. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.26 and a current ratio of 1.26. The stock has a market cap of $2,735.27, a PE ratio of -20.37 and a beta of 1.62. Immunomedics has a twelve month low of $5.00 and a twelve month high of $18.93.
In other news, Director David M. Goldenberg sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 7th. The shares were sold at an average price of $17.50, for a total value of $350,000.00. Following the transaction, the director now owns 1,774,285 shares in the company, valued at $31,049,987.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David M. Goldenberg sold 17,729 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $17.09, for a total transaction of $302,988.61. Following the completion of the transaction, the director now owns 1,774,285 shares in the company, valued at approximately $30,322,530.65. The disclosure for this sale can be found here. Insiders have sold 77,729 shares of company stock worth $1,342,589 over the last quarter. Company insiders own 14.80% of the company’s stock.
Several institutional investors have recently modified their holdings of IMMU. Calton & Associates Inc. bought a new position in Immunomedics in the 4th quarter valued at $135,000. Xact Kapitalforvaltning AB purchased a new stake in Immunomedics during the 4th quarter valued at approximately $193,000. Sapphire Star Partners LP purchased a new stake in Immunomedics during the 4th quarter valued at approximately $323,000. Virtus Fund Advisers LLC purchased a new stake in Immunomedics during the 4th quarter valued at approximately $456,000. Finally, Teacher Retirement System of Texas purchased a new stake in Immunomedics during the 4th quarter valued at approximately $524,000. Hedge funds and other institutional investors own 74.51% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “-$0.13 Earnings Per Share Expected for Immunomedics (IMMU) This Quarter” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/22/0-13-earnings-per-share-expected-for-immunomedics-immu-this-quarter.html.
Immunomedics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers.
Get a free copy of the Zacks research report on Immunomedics (IMMU)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.